Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase.
Perusini MA, Andrews C, Atenafu EG, Gupta V, Maze D, Schuh AC, Yee KW, Bankar A, Davidson MB, Richard-Carpentier G, Chan SM, Sibai J, Schimmer AD, Minden MD, Sibai H. Perusini MA, et al. Among authors: sibai h. Hematology. 2024 Dec;29(1):2329027. doi: 10.1080/16078454.2024.2329027. Epub 2024 Mar 25. Hematology. 2024. PMID: 38526239
Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
Sibai H, Chen R, Liu X, Falcone U, Schimmer A, Schuh A, Law A, McNamara C, Maze D, Yee K, Minden M, Chan SM, Gupta V, Murphy T, Sakurai N, Atenafu EG, Brandwein JM, Seki JT. Sibai H, et al. Br J Haematol. 2020 Dec;191(5):748-754. doi: 10.1111/bjh.16695. Epub 2020 May 12. Br J Haematol. 2020. PMID: 32395867 Free article. Clinical Trial.
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
Chen R, Atenafu EG, Seki J, Liu X, Chan S, Gupta V, Maze D, Shuh AC, Minden MD, Yee K, Schimmer AD, Sibai H. Chen R, et al. Among authors: sibai h. Br J Haematol. 2023 May;201(4):645-652. doi: 10.1111/bjh.18683. Epub 2023 Feb 16. Br J Haematol. 2023. PMID: 36794878
Safety of re-challenging adults with acute lymphoblastic leukemia with PEG-asparaginase-induced severe hypertriglyceridemia when treated with a pediatric-inspired regimen.
Al Nabhani I, Andrews C, Sibai J, Atenafu E, Young T, Chan SM, Gupta V, Maze D, Schimmer AD, Schuh AC, Yee K, Sibai H. Al Nabhani I, et al. Among authors: sibai h, sibai j. EJHaem. 2022 Nov 4;4(1):232-235. doi: 10.1002/jha2.607. eCollection 2023 Feb. EJHaem. 2022. PMID: 36819167 Free PMC article.
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
Farshchi Zarabi S, Chan S, Gupta V, Khalaf D, Lutynski A, Minden MD, Rostom A, Rydlewski A, Schuh AC, Sibai H, Yee KWL, Schimmer AD. Farshchi Zarabi S, et al. Among authors: sibai h. Leuk Lymphoma. 2018 Jan;59(1):237-240. doi: 10.1080/10428194.2017.1323273. Epub 2017 Jun 9. Leuk Lymphoma. 2018. PMID: 28595467 No abstract available.
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
Kavanagh S, Heath E, Hurren R, Gronda M, Barghout SH, Liyanage SU, Siriwardena TP, Claudio J, Zhang T, Sukhai M, Stockley TL, Kamel-Reid S, Rostom A, Lutynski A, Khalaf D, Rydlewski A, Chan SM, Gupta V, Maze D, Sibai H, Schuh AC, Yee K, Minden MD, Schimmer AD. Kavanagh S, et al. Among authors: sibai h. Leuk Res. 2018 May;68:22-28. doi: 10.1016/j.leukres.2018.02.012. Epub 2018 Feb 20. Leuk Res. 2018. PMID: 29518628
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
Murphy T, Zou J, Daher-Reyes GS, Arruda A, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Korulla M, Stockley T, Kamel-Reid S, Maze D, Tierens A, Bratman SV, Schuh AC, Chan SM. Murphy T, et al. Among authors: sibai h. Blood Adv. 2019 Aug 13;3(15):2307-2311. doi: 10.1182/bloodadvances.2019000306. Blood Adv. 2019. PMID: 31371380 Free PMC article.
84 results